

REMARKS

Submission of Sequence Listing

Applicants hereby submit a corrected nucleotide/amino acid sequence listing.

Applicants gratefully acknowledge the error report that accompanied the Notice, and have corrected the errors identified therein in compliance with the requirements of 37 C.F.R. § 1.821-1.825. The corrected sequence listing is submitted herewith in both paper copy and computer-readable form. The undersigned hereby verifies that the content of the paper copy and the computer-readable form are identical. The undersigned verifies that the corrected sequence listing does not include any new matter.


Amendments to the Specification

The specification is amended to correct typographical errors. Specifically, the paragraph bridging lines 22-28 of page 30 is amended to properly refer to the indicated sequences using the correct SEQ ID NOs. This amendment adds no new matter to the application. A marked-up copy of the paragraph, indicating the changes made thereto, is attached.

Conclusion

The application is considered in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



M. Daniel Hefner, Reg. No. 41,826
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: April 25, 2003



PATENT
Attorney Docket No. 219604
Client Reference No. KAUS430501

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

KASID et al.

Group Art Unit: unassigned

Application No. 10/075,994

Examiner: unassigned

Filing Date: February 15, 2002

For: CHEMOSENSITIZING WITH LIPOSOMES
CONTAINING OLIGONUCLEOTIDES

INDICATION OF AMENDMENTS MADE TO SPECIFICATION

Note, deleted text appears in brackets, added text appears in underlining and with highlighting because certain portions of the text already are underlined.

A 20-mer phosphorothioate antisense ODN (ISIS 5132/5132: 5' TCC-CGC-CTG-TGA-CAT-GCA-TT-3' (SEQ ID NO:5[4]) corresponding to the 3' untranslated region (3'UTR) of human *c-ras*-1 mRNA and a seven base mismatched phosphorothioate antisense ODN (ISIS 10353/10353; 5'-TCC-CGC-GCA-CTT-GAT-GCA-TT-3') (SEQ ID NO:6[5]) were designed and synthesized as described previously (Monia et al., 1996a,b). A 20-mer phosphorothioate sense ODN (5'-ATT-GCA-TGT-CAC-AGG-CGG-GA-3') (SEQ ID NO:7[6]) was synthesized at Loftstrand Labs Limited (Gaithersburg, MD) as described previously (Soldatenkov et al., 1997).